DKK3 and neoplasm: As example, in a phase I/IIa clinical study with 18 patients with adenocarcinoma of the prostate, the intra-tumoral administration of Ad-REIC prolonged recurrence-free survival, with tumor degeneration and a significant number of TIL (tumor-infiltrating lymphocytes) being observed in the targeted areas of the tumor [124].